Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

78284

Spike S1 (P.1; Gamma Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit

BPS Bioscience

DESCRIPTION

The Spike S1 (P.1; Gamma Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (P.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

DETAILS

  • Notes: Troubleshooting Guide: Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com
  • Shiptemp: -80°C (dry ice)
  • Synonyms: coronavirus, SARS-CoV-2 inhibition kit, ACE2 inhibition kit, SARS TR-FRET kit, ACE2 homogenous kit, covid, covid-19, covid19, Sars-cov-2, sars cov 2, P1, P.1 Variant, Gamma Variant, Gamma assay kit
  • Warnings: Avoid freeze/thaw cycles.
  • Category: Kinases
  • Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection.  A variant called P.1, also known as Gamma variant, was first identified in Brazil in the summer of 2020. This variant has many mutations in the Spike protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y) that may lead to higher transmissibility and infectivity.
  • Constructs: Keep final DMSO concentration at or below 1%.
  • References: 1. Hoffmann, M. et al. Cell, 181:1-102. Yan, R. et al. 2020. Science 367(6485):1444-1448
  • Description: The Spike S1 (P.1; Gamma Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (P.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
  • Methodology: TR-FRET
  • Supplied As: Homogeneous 384 reaction format
  • Unspsc Code: 41121811
  • Unspsc Name: Laboratory microchemistry kits
  • Applications: This kit is useful for screening for inhibitors of the interaction between SARS-CoV-2 Spike S1 (P.1) and human ACE2.
  • Product Type: Assay Kit
  • Biosafety Level: Not applicable (BSL-1)
  • Related Products: 78283, 78287, 78288, 78289
  • Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
  • Scientific Category: Coronavirus
  • Instructions for Use: See assay protocol for detailed instructions.